Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The administration of Anamorelin in patients with Stage III-IV non-small cell lung
cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and
muscle strength.